Immunoglobulin during intrauterine transfusion for Rh disease
Treatments studied
Part of Blood & lymphatic, Genetic & congenital, Immune system & allergy, Women’s health & pregnancy clinical trials.
This trial tests whether giving a medication called intravenous immunoglobulin (a type of antibody treatment) directly to the baby during a blood transfusion in the womb can improve the baby's health outcomes in pregnancies affected by Rh blood type incompatibility. It aims to see if this added treatment helps reduce complications and improves survival and wellbeing of the baby after birth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You and your baby's blood type are Rh-negative and Rh-positive, causing Rh incompatibility.
- You are about to receive your first transfusion to treat the baby's anemia while still in the womb.
- You are at least 20 weeks pregnant when you have this first transfusion.
- Your baby does not have any major birth defects or chromosome disorders.
- You are not pregnant with twins or more.
- You do not have severe kidney problems, and you have not had a severe allergic reaction to immunoglobulin in the past.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking at a new way to detect bleeding between the mother and baby during pregnancy (called fetomaternal hemorrhage), which can lead to a blood problem in the newborn called hemolytic disease. The goal is to see if this test can help diagnose the condition earlier and hopefully improve care for the baby.
This study tracks pregnancies affected by hemolytic disease of the fetus and newborn (HDFN). It collects information to better understand the condition and improve care. You may join if you are pregnant with a history of a prior affected pregnancy and have a current antibody that could harm your baby.
This Phase 1 study tests whether repeatedly adding fluid into the amniotic sac (amnioinfusion) can help babies with very severe kidney problems before birth. The goal is to see if this “regenerative therapy” is safe and potentially beneficial, while closely tracking pregnancy and baby outcomes.
This Phase 3 trial tests nipocalimab (an antibody medicine) to help prevent severe blood breakdown in a baby when a parent has certain blood antibodies. It enrolls people who previously had severe hemolytic disease in a past pregnancy and who are currently early in pregnancy with the same risk antibodies.
This study tests whether using cord blood (the blood left in the umbilical cord after birth) that is rich in fetal hemoglobin (the type of hemoglobin babies have before birth) can make blood transfusions safer and more personalized for very premature babies. If this works, it might reduce the need for multiple transfusions and improve outcomes for preterm infants.
This trial tests whether giving intravenous immunoglobulin (IVIG) early after birth can help prevent or treat a serious lung condition called bronchopulmonary dysplasia (BPD) in babies born at 28 weeks or earlier. It may help reduce the need for breathing support and oxygen.
Hear when a new Fetal Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.